Compare KNSL & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KNSL | PRAX |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 9.6B |
| IPO Year | 2016 | 2020 |
| Metric | KNSL | PRAX |
|---|---|---|
| Price | $365.88 | $308.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 15 |
| Target Price | $455.40 | ★ $572.13 |
| AVG Volume (30 Days) | 266.5K | ★ 331.9K |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.27% | N/A |
| EPS Growth | ★ 21.77 | N/A |
| EPS | ★ 21.65 | N/A |
| Revenue | ★ $1,873,987,000.00 | N/A |
| Revenue This Year | $6.46 | N/A |
| Revenue Next Year | $8.77 | $6,395.88 |
| P/E Ratio | $17.24 | ★ N/A |
| Revenue Growth | ★ 18.04 | N/A |
| 52 Week Low | $341.06 | $26.70 |
| 52 Week High | $512.76 | $354.87 |
| Indicator | KNSL | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 37.91 | 43.30 |
| Support Level | $345.03 | $290.36 |
| Resistance Level | $400.98 | $322.32 |
| Average True Range (ATR) | 10.10 | 18.62 |
| MACD | -1.18 | -5.00 |
| Stochastic Oscillator | 9.53 | 26.55 |
Kinsale Capital Group Inc is an insurance holding company. The company is engaged in offering property, casualty, and specialty insurance products. It offers specialty insurance products for allied health, healthcare, life sciences, professional, and a public entity. The company operates in only one reportable segment which is the Excess and Surplus Lines Insurance segment, which includes commercial excess and surplus lines liability and property insurance products through its underwriting divisions. The company generates revenues in the form of premiums and investment income.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.